glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection

Part of Weight Loss Drug Comparison Index.

Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection

Orforglipron is a daily pill, approved as Foundayo for adult weight management. Tirzepatide is a weekly injection, sold as Zepbound and Mounjaro for different approved uses. Tirzepatide’s obesity trials reported larger average weight reductions, but there is no direct weight-loss comparison with orforglipron in the evidence reviewed here. Calling it “twice as effective” overstates what separate trials can establish.
If you have type 2 diabetes, the distinction between Mounjaro and Zepbound matters as much as pill versus injection. This page covers the drug and indication differences; the orforglipron vs Zepbound comparison covers current weight-management pricing and access in more detail.
Reviewed September 8, 2026, against the current Foundayo, Mounjaro and Zepbound labels.

Side-by-Side Comparison

Foundayo (orforglipron)Tirzepatide
DeveloperEli LillyEli Lilly
DeliveryDaily oral tabletWeekly injection under the skin
Molecule and receptorsNon-peptide; GLP-1Peptide; GLP-1 and GIP
Weight-management brandFoundayoZepbound
Diabetes-related approvalNot in the current Foundayo labelMounjaro
Adult maximum labeled dose17.2 mg daily15 mg weekly
Fasting requirementNoneNone
Other relevant indicationNo cardiovascular or OSA indication in the current labelProduct-specific cardiovascular and OSA indications; see below
Zepbound is approved for adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is approved for glycemic control in type 2 diabetes, including patients aged 10 years and older. Its August 2026 label also includes reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Those uses cannot be transferred automatically between brand labels. Sources: Zepbound label, section 1 and Mounjaro label, section 1.

How the Mechanisms Differ

Orforglipron: One Receptor, Oral Delivery

Orforglipron is a small-molecule GLP-1 receptor agonist that reduces calorie intake through effects on appetite. Foundayo can be taken with or without food and stored at room temperature. It still has drug interactions and a gradual escalation schedule. Foundayo label, sections 2, 7, 12 and 16

Research descriptions of its receptor signaling do not establish a fixed weight-loss ceiling or a clinical safety advantage. The relevant question is what trials and the approved label show for the condition being treated.

Tirzepatide: Two Receptors, Weekly Injection

Tirzepatide activates GLP-1 and GIP receptors and reduces calorie intake. Its effects on glucose control and weight are evaluated in different trial programs. A second receptor is a mechanistic difference; receptor count alone cannot explain the size of a difference between unrelated clinical trials. Mounjaro clinical pharmacology

Weight Loss Comparison

Phase 3 Trial Results

The following are separate 72-week obesity trials in adults without diabetes, not a randomized comparison between the two drugs. Values below come from the current labels’ intention-to-treat analyses, which include all randomized participants and impute missing outcomes.

Swipe sideways to see every column.

Treatment as described in current labelTrialTotal randomizedMean weight change at 72 weeks
Foundayo-equivalent 5.5 mg dailyATTAIN-13,127−7.4%
Foundayo-equivalent 9 mg dailyATTAIN-13,127−8.3%
Foundayo-equivalent 17.2 mg dailyATTAIN-13,127−11.1%
Tirzepatide 5 mg weeklySURMOUNT-12,539−15.0%
Tirzepatide 10 mg weeklySURMOUNT-12,539−19.5%
Tirzepatide 15 mg weeklySURMOUNT-12,539−20.9%
Placebo groups lost 2.1% in the Foundayo label analysis and 3.1% in the Zepbound label analysis. Sources: Foundayo label, Trial 1/Table 6 and Zepbound label, Study 1/Table 2.
The often-quoted 12.4% for orforglipron and 22.5% for tirzepatide come from the trials’ efficacy estimands, which handle treatment discontinuation differently. The orforglipron result used the 36 mg investigational formulation; it is not a marketed Foundayo strength. The Foundayo label explicitly expresses trial doses as equivalent marketed doses. ATTAIN-1 publication release, SURMOUNT-1 publication release

Weight Loss Thresholds

Weight reduction at week 72Foundayo-equivalent 17.2 mg, ATTAIN-1Tirzepatide 15 mg, SURMOUNT-1
At least 5%71.5%90.9%
At least 10%54.5%83.5%
At least 15%35.9%70.6%
At least 20%18.4%56.7%
These are the current labels’ intention-to-treat responder estimates from the same separate trials above. They show the range of responses within each study, not an individual’s chance of success or a head-to-head difference. Foundayo label, Zepbound label

Important Caveats

Both studies enrolled adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes. Their populations, protocols and missing-data methods differed. Do not use these obesity results to forecast diabetes treatment outcomes, and do not choose a drug solely because a target percentage sits above or below a trial average.

Side Effects Comparison

Both medicines commonly cause nausea, diarrhea, vomiting and constipation. The table preserves trial-specific rates, with the named doses, for context. The rates cannot establish which medicine causes more symptoms in comparable patients, because they came from separate studies.
Reported adverse eventOrforglipron 36 mg trial formulation, ATTAIN-1Tirzepatide 15 mg, SURMOUNT-1
Nausea33.7%31.0%
Diarrhea23.1%23.0%
Vomiting24.0%12.2%
Constipation25.4%11.7%
Stopped treatment because of adverse events10.3%6.2%
Sources: ATTAIN-1 full results and SURMOUNT-1 full results. These are participants assigned the stated doses, not pooled brand-label safety rates. There is no established explanation here that daily pills cause more gastrointestinal exposure than weekly injections.
Both current labels include a boxed thyroid C-cell tumor warning and contraindications involving medullary thyroid carcinoma or MEN 2, as well as warnings for pancreatitis, severe gastrointestinal reactions and dehydration-related kidney injury. Foundayo also has specific CYP3A4 and simvastatin interactions. Tirzepatide can cause injection-site reactions. These differences belong in a clinician or pharmacist review, not a blanket claim that one drug is safer. Foundayo label, Zepbound label

Convenience vs Efficacy: The Core Trade-Off

The Case for Orforglipron

  • A daily tablet avoids injections and can fit someone who does not want to use a pen or vial.
  • Foundayo does not require the fasting routine used for oral semaglutide.
  • Room-temperature storage can simplify travel, within the label’s storage conditions.
These are administration advantages. They do not establish a lower treatment cost, easier prescribing or suitability for every patient. Foundayo prescribing information

The Case for Tirzepatide

  • Weekly administration may fit someone who finds daily medicines difficult to remember.
  • Zepbound has weight-management and obesity-related OSA indications.
  • Mounjaro has diabetes and eligible-adult cardiovascular indications, which can matter when the treatment goal goes beyond weight.
The August 2026 Mounjaro label is the relevant source for its cardiovascular use. A statement that “SURPASS-CVOT reduced events by 10%” without its comparator and analysis does not explain that indication and should not be presented as a Zepbound benefit. Mounjaro label

Who Might Choose Which?

Discuss what is being treated, the medicine’s labeled use, your previous response, side effects, interactions, ability to follow the routine and ongoing cost. A daily pill is worth considering when injections are a barrier, but it should not replace diabetes or cardiovascular treatment without a plan for those conditions. If a current medicine is working and tolerable, convenience alone is not a reason you must switch.

Switching Between the Two

ATTAIN-MAINTAIN randomized 376 participants who had completed SURMOUNT-5 to orforglipron or placebo for another 52 weeks. It studied maintenance after prior injectable treatment, not initial weight loss versus tirzepatide. Lilly reported the detailed results in May 2026, alongside publication in Nature Medicine. Detailed ATTAIN-MAINTAIN release
In the prior-Zepbound cohort, people switching to orforglipron regained 5.0 kg on average over the maintenance year in the reported efficacy analysis. That is weight change after switching, not a 5 kg difference from continuing Zepbound. The comparator was placebo, and rescue treatment was allowed under specified conditions.
The trial supports a clinician-led discussion about oral maintenance, with possible regain. It does not supply a milligram conversion or prove equivalence to staying on tirzepatide. The Foundayo and Zepbound labels do not recommend combining these GLP-1-active medicines. Foundayo label, Zepbound label

Lilly’s Portfolio Strategy

Lilly now has approved oral weight management with Foundayo and injectable treatment with tirzepatide, while retatrutide remains investigational. These products have overlapping treatment goals, but different indications and evidence. Sales forecasts and claims about “maximum efficacy” do not determine the right prescription.

For someone comparing pills and injections, the practical question is whether the drug fits the condition and can be continued safely and affordably. See oral vs injectable options for the formulation differences.

Where Retatrutide Fits

Retatrutide activates GIP, GLP-1 and glucagon receptors. In Lilly’s TRIUMPH-4 topline report, the 12 mg group had 28.7% average weight loss at 68 weeks using the efficacy estimand, in adults with obesity or overweight and knee osteoarthritis, without diabetes. This was a placebo-controlled study of an investigational injection, not a comparison with Foundayo or Zepbound. TRIUMPH-4 results
More receptor targets do not by themselves prove a better treatment. For the broader evidence, see Retatrutide vs Tirzepatide and Retatrutide vs Orforglipron.

Frequently Asked Questions

Is orforglipron as effective as tirzepatide for weight loss?

Tirzepatide trials reported larger average weight reductions, but the drugs were not compared directly in those studies. Different populations and analyses prevent a claim that one is “twice as effective.” Your likely response also depends on the condition being treated and whether you can continue the medicine.

Can I take orforglipron instead of Zepbound?

Foundayo is now an approved weight-management option for eligible adults. A prescriber can consider it if you prefer a pill, but switching may involve weight regain and requires a treatment plan. Do not take both together or convert the doses yourself.

Are orforglipron and tirzepatide made by the same company?

Yes. Lilly markets orforglipron as Foundayo and tirzepatide as Zepbound and Mounjaro. The brands have different labeled indications. Lilly is also studying retatrutide, which remains investigational.

Why does orforglipron produce less weight loss than tirzepatide?

The drugs have different mechanisms: orforglipron activates GLP-1 receptors, while tirzepatide also activates GIP receptors. But the separate trials cannot isolate why their averages differed. Receptor count alone does not establish a weight-loss ceiling or predict an individual result.

When will orforglipron be available?

It is available in the US as prescription Foundayo for adult weight management. Its current label does not include a diabetes or cardiovascular indication.

Can I switch from tirzepatide to orforglipron?

ATTAIN-MAINTAIN supports discussing oral maintenance with a clinician. Participants switching from Zepbound to orforglipron regained an average 5.0 kg over 52 weeks in the reported efficacy analysis. The trial compared switching with placebo, not with continued tirzepatide, so it does not establish equivalent maintenance.

What are the side effects of orforglipron compared to tirzepatide?

Both can cause gastrointestinal symptoms and serious adverse effects. Tirzepatide can also cause injection-site reactions, while Foundayo has specific medicine interactions. Rates from unrelated trials cannot establish which will be better tolerated for you.

Sources

  1. Eli Lilly. Foundayo prescribing information.
  2. Eli Lilly. Zepbound prescribing information.
  3. Eli Lilly. Mounjaro prescribing information. August 2026 indication update.
  4. Eli Lilly. ATTAIN-1 full results. September 16, 2025.
  5. Eli Lilly. SURMOUNT-1 full results. June 4, 2022.
  6. Eli Lilly. ATTAIN-MAINTAIN detailed results. May 12, 2026.
  7. Eli Lilly. TRIUMPH-4 topline results. December 11, 2025.
This article is for information, not a prescription or switching plan. Foundayo, Zepbound and Mounjaro are approved for their respective labeled uses; retatrutide remains investigational. Discuss treatment with your clinician. This site is not affiliated with Eli Lilly or any pharmaceutical manufacturer.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo, Zepbound and Mounjaro are FDA-approved for their respective labeled indications. Their uses differ; retatrutide remains investigational.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →